Phase 2 N=168 A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
Anthrax
Primary: Toxin Neutralizing Antibody (TNA) Level at Day 63 — 56.8; 100; 100; 90.2 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=189 A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
Ovarian Cancer
Primary: Progression-free Survival — 23.7 Months
N/A N=401 Improving Chronic Pain Treatment in Primary Care
Pain · Chronic Disease · Depression
Primary: Adjusted Change in Pain-related Function (Roland Disability Score) — -1.4; -0.2 units on a scale
N/A N=6 Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
Lung Cancer · Non Small Cell Lung Carcinoma · Hypermethylation
Primary: Percentage of Patients Showing a Presence of Methylated Tumor Suppressor Genes in Their Tumor Tissue and/or Serum Achieving Partial or Complete Response to Protocol…
N/A N=2,579 PROMISE EBF: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV in Sub-Saharan Africa
Diarrhea
Primary: Exclusive Breastfeeding Rates in Burkina Faso — 310; 161 participants
Phase 4 N=25 Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces
Aging
Primary: Hydration Level — 53.19; 46.75 AU (arbitrary unit) — p=<0.05
Phase 2 N=54 Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy
Breast Cancer · Precancerous Condition
Primary: Change in Isothiocyanate in Urine Samples as Assessed at Baseline and After Completion of Study Therapy — 1.00; -0.05 µM/mM creatinine
Phase 3 N=217 A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
Non-Small Cell Lung Cancer
Primary: Investigator-assessed Duration of Progression-free Survival — 11.0; 5.5 Months
Phase 4 N=24 Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients
Obesity
Primary: Gastric Emptying of Solids Half-Time (T 1/2) — 109; 88 minutes — p=0.057
Phase 2 N=45 Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Hepatitis C, Chronic
Primary: Number of Participants Whose Platelet Count Increased From a Baseline Count of < 80 Gi/L to a Count >=100 Gi/L During Part 1 — 43 Participants
Phase 3 N=313 A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 6.86; 7.00 weeks — p=0.671
Phase 4 N=262 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia
Dyspepsia · Compliance · Depression
Primary: Compliance of Flupentixol-Melitracen — 44; 28; 31 participants
Phase 2 N=20 Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty
Total Hip Arthroplasty · Muscle Injury
Primary: Change From Day 0 to Week 26 in the Maximal Voluntary Isometric Contraction (MVIC) Moment of the Injured Side to Assess Gluteus Medius Strength. — 31.17; 20.36; 5.43…
Phase 4 N=40 Atazanavir and Lamivudine for Treatment Simplification
HIV Infections
Primary: Number of Patients With Virological Failure (Two Consecutive Measures of HIV-RNA Higher Than 50 Copies/mL or a Single Measure Higher Than 1000 Copies/mL) Within 48 Weeks…
Phase 3 N=424 A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Died (All Participants; Data Cutoff: 07 September 2010) — 81.0; 77.8 percentage of participants